Repros Therapeutics Inc (NASDAQ:RPRX), the biopharmaceutical company focused on drugs that treat male and female reproductive disorders, posted a wider Q3 loss as sales fell. The net loss was $7.4 million or $0.32 per share as compared to a net loss of $6.0 million or $0.26 per share for the same period in 2013. Analysts had expected a loss of $0.40. Total revenues and other income was $2,000 for the three month period ended September 30, 2014 as compared to $3,000 for the same period in the prior year. Repros Therapeutics Inc (NASDAQ:RPRX) had cash and cash equivalents of approximately $53.1 million as of September 30, 2014 as compared to $75.8 million as of December 31, 2013. The shares recently traded at $9.68 with a 52-week range of $5.92 - $22.57.Howard Hughes Corp (NYSE:HHC), a commercial real estate company, posted mixed Q3 results, with earnings up sharply year-over-year and missing on revenue. Net income attributable to common stockholders was $45.6 million, or $0.48 per diluted common share, compared with $7.3 million, or $0.17 the year earlier. Adjusted earnings were $15.5 million, or $0.36 per share compared with $11.1 million, or $0.26 the year before, below a single analyst forecast for $0.70, if comparable, according to Capital IQ.Revenue was $119.2 million, up from $99.6 million in the year-earlier period. That's below the $137 million analysts had expected. Howard Hughes Corp (NYSE:HHC) also said Monday that it has secured a $600 million non-recourse construction loan from Blackstone Real Estate Debt Strategies for the development of Waiea and Anaha, the first two condominium towers at Ward Village, Honolulu. The shares are up 0.3% pre-bell at $149.95 with a 52-week spread of $105.51 - $160.62.GTx Inc. (NASDAQ:GTXI) said its Q3 net loss narrowed year-on-year and beat the consensus of analysts polled by Capital IQ. Net loss totaled $4.9 million, or $0.06 per diluted share, improving from a net loss of $8.9 million, or $0.14 per diluted share in the year-ago period. Analysts were expecting a net loss of $0.10 per share. Earlier on Monday, the biopharmaceutical company announced it entered into a securities purchase agreement for the sale of approximately $43.4 million of its common stock and warrants to purchase common stock in a private placement, which will result in net proceeds of about $42.8 million. The group of accredited investors includes Biotechnology Value Fund, L. P. and other affiliates of BVF Partners L.P., certain existing GTx Inc. (NASDAQ:GTXI) stockholders and certain members of the GTx management team and board of directors.Pursuant to the terms of the securities purchase agreement, at the closing of the private placement, GTx will receive approximately $43.4 million in gross proceeds from the sale of 64,311,112 shares of GTx common stock and the issuance of warrants for the purchase of 64,311,112 additional shares of GTx common stock. The per unit purchase price of a share of GTx common stock and a warrant to purchase a share of GTx common stock is $0.675. The warrants will have a per share exercise price of $0.85 and will be exercisable for a four year period as determined in accordance with the terms of the warrants. GTXI closed higher at $0.57 on Friday, in a 52-week range of $0.41 - $2.35.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
